Special Issue

Molecular Pathology of Brain Tumors

Message from the Guest Editor

CNS tumors are cancers with the worst prognosis among the common cancers, and they are the most important cause of cancer death in children. Since the publication of the WHO Classification of CNS tumors (2021), the molecular pathology of brain tumors has become a critical diagnostic, prognostic, and treatment-predictive biomarker. Newer techniques, like AI or long-read sequencing, impact the way histological and molecular data are interpreted. In this Special Issue, we bring together experts on the following areas: the molecular pathology of pediatric primary CNS lymphoma, from researchers in Hong Kong; the relationship between MGMT hypermethylation and necrosis, a key histological feature of glioblastoma, from researchers in Sydney; AI and histology and molecular pathology of brain tumors, from researchers in Vancouver; and long-read sequencing to discover structural variants in pediatric brain tumors and how NTRK fusion impacts the results of the use of NTRK inhibitors in both children and adults, from researchers in Seoul.

Guest Editor

Prof. Dr. Ho-Keung NG

Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Sha Tin, Hong Kong, China

Deadline for manuscript submissions

15 March 2026

Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/
cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing
both clinical and basic science issues related to cancer
research. The journal is publishing in Open Access
format, which will certainly evolve to ensure that the
journal takes full advantage of the rapidly changing
world of information and knowledge dissemination. It
publishes high-quality clinical, translational, and basic
science research on cancer prevention, initiation,
progression, and treatment, as well as other related
topics, particularly to capture the most seminal studies
in the rapidly growing area of immunology,
immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The
University of Texas MD Anderson Cancer Center, Houston, TX 77030,
USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed,
PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)